Do you want to read an article? Please log in or register.
Impact of uveal melanoma thickness on post-plaque radiotherapy outcomes in the prophylactic anti-vascular endothelial growth factor era in 1131 patients
Ocular Oncology
Related content
Macular DiseasesOcular OncologyRetinal Diseases
Nomogram for visual acuity outcome after iodine-125 plaque radiotherapy and prophylactic intravitreal bevacizumab for uveal melanoma in 1131 patients
Br J Ophthalmol.
Dalvin LA, Zhang Q, Hamershock RA, Chang M, Yu MD, Mashayekhi A, Shields CL
doi: 10.1136/bjophthalmol-2019-314686.
COMMENTED
Macular Diseases
Anti-vascular endothelial growth factor in neovascular age-related macular degeneration - a systematic review of the impact of anti-VEGF on patient outcomes and healthcare systems
★ 2
Recommended and commented by
Prof. Dr Stephan Michels, Faculty Member
BMC Ophthalmol.
Finger RP, Daien V, Eldem BM, Talks JS, Korobelnik JF, Mitchell P, Sakamoto T, Wong TY, Pantiri K, Carrasco J
doi: 10.1186/s12886-020-01554-2.
COMMENTED
Ocular Oncology
Visual Outcome at 4 Years Following Plaque Radiotherapy and Prophylactic Intravitreal Bevacizumab (Every 4 Months for 2 Years) for Uveal Melanoma: Comparison With Nonrandomized Historical Control Individuals
★ 3
Recommended and commented by
Dr habil. Gábor Márk Somfai, PhD, Faculty Member
doi: 10.1001/jamaophthalmol.2019.5132.
Macular Diseases
Visual Outcomes Based on Early Response to Anti-Vascular Endothelial Growth Factor Treatment for Diabetic Macular Edema
Ophthalmologica.
Koyanagi Y, Yoshida S, Kobayashi Y, Kubo Y, Nakama T, Ishikawa K, Nakao S, Hisatomi T, Ikeda Y, Oshima Y, Ishibashi T, Sonoda KH
doi: 10.1159/000481711.
COMMENTED
Macular DiseasesRetinal Diseases
IMPACT OF LONG-TERM INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR ON PREEXISTING MICROSTRUCTURAL ALTERATIONS IN DIABETIC MACULAR EDEMA
Retina.
Wirth MA, Wons J, Freiberg FJ, Becker MD, Michels S
doi: 10.1097/IAE.
Macular Diseases
Factors Associated With Visual Acuity and Central Subfield Thickness Changes When Treating Diabetic Macular Edema With Anti-Vascular Endothelial Growth Factor Therapy: An Exploratory Analysis of the Protocol T Randomized Clinical Trial
JAMA Ophthalmol.
Bressler SB, Odia I, Maguire MG, Dhoot DS, Glassman AR, Jampol LM, Marcus DM, Solomon SD, Sun JK; Diabetic Retinopathy Clinical Research Network
doi: 10.1001/jamaophthalmol.
COMMENTED
Macular Diseases
Association of Intravitreal Anti-Vascular Endothelial Growth Factor Therapy With Risk of Stroke, Myocardial Infarction, and Death in Patients With Exudative Age-Related Macular Degeneration
JAMA Ophthalmol.
Dalvin LA, Starr MR, AbouChehade JE, Damento GM, Garcia M, Shah SM, Hodge DO, Meissner I, Bakri SJ,
Iezzi R
doi: 10.1001/jamaophthalmol.
COMMENTED
Macular Diseases
Associations of Variation in Retinal Thickness With Visual Acuity and Anatomic Outcomes in Eyes With Neovascular Age-Related Macular Degeneration Lesions Treated With Anti-Vascular Endothelial Growth Factor Agents
★ 2
Recommended and commented by
Dr habil. Gábor Márk Somfai, PhD, Faculty Member
JAMA Ophthalmol
Evans RN, Reeves BC, Maguire MG, Martin DF, Muldrew A, Peto T, Rogers C, Chakravarthy U
doi: 10.1001/jamaophthalmol.2020.3001
Macular Diseases
Simulating an Anti-Vascular Endothelial Growth Factor Switch in Neovascular Age-Related Macular Degeneration: A HARBOR Subanalysis
Ophthalmology.
Zarbin M, Tsuboi M, Hill LF, Stoilov I
doi: 10.1016/j.ophtha.2019.01.003.